GRAHAM MITCHELL: Open Payments
NPI 1346419736 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,792 in 185 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $3,252 · 2025 $3,792
Food & beverage: $3,792
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 27 | $537 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $442 |
| ABBVIE INC. | 24 | $396 |
| Axsome Therapeutics, Inc. | 16 | $359 |
| Alkermes, Inc. | 13 | $334 |
| Vanda Pharmaceuticals Inc. | 14 | $285 |
| Lundbeck LLC | 16 | $255 |
| Janssen Pharmaceuticals, Inc | 10 | $247 |
| Teva Pharmaceuticals USA, Inc. | 11 | $236 |
| Supernus Pharmaceuticals, Inc. | 11 | $217 |
Products named: REXULTI, CAPLYTA, VRAYLAR, Auvelity, ARISTADA, Qelbree, INGREZZA, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
